Nivolumab for previously treated squamous oesophageal carcinoma
Mené sur 419 patients atteints d'un carcinome épidermoïde de l'œsophage non résécable de stade avancé, réfractaire ou intolérant à une chimiothérapie à base de fluoropyrimidine et de sels de platine, cet essai international de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité du nivolumab et d'une chimiothérapie de deuxième ligne (paclitaxel ou docétaxel)
Despite accounting for more than 90% of oesophageal cancers globally, oesophageal squamous cell carcinoma has historically been underserved by research. High-quality data to support therapeutic decision making in patients with advanced oesophageal squamous cell carcinoma are scarce, and treatment is frequently extrapolated from gastroesophageal adenocarcinoma trials. Encouragingly, the molecular distinction of oesophageal squamous cell carcinoma from adenocarcinoma has paved the way for clinical trials focusing exclusively on oesophageal squamous cell carcinoma
The Lancet Oncology , commentaire, 2018